Shanghai Aladdin Biochemical Technology Co. Ltd. A (688179) - Net Assets
Based on the latest financial reports, Shanghai Aladdin Biochemical Technology Co. Ltd. A (688179) has net assets worth CN¥1.19 Billion CNY (≈ $173.99 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.61 Billion ≈ $381.51 Million USD) and total liabilities (CN¥1.42 Billion ≈ $207.52 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 688179 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.19 Billion |
| % of Total Assets | 45.61% |
| Annual Growth Rate | 22.37% |
| 5-Year Change | 35.49% |
| 10-Year Change | N/A |
| Growth Volatility | 48.04 |
Shanghai Aladdin Biochemical Technology Co. Ltd. A - Net Assets Trend (2019–2025)
This chart illustrates how Shanghai Aladdin Biochemical Technology Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See Shanghai Aladdin Biochemical Technology (688179) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Shanghai Aladdin Biochemical Technology Co. Ltd. A (2019–2025)
The table below shows the annual net assets of Shanghai Aladdin Biochemical Technology Co. Ltd. A from 2019 to 2025. For live valuation and market cap data, see Shanghai Aladdin Biochemical Technology market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.16 Billion ≈ $170.17 Million |
+1.73% |
| 2024-12-31 | CN¥1.14 Billion ≈ $167.28 Million |
+10.30% |
| 2023-12-31 | CN¥1.04 Billion ≈ $151.66 Million |
+6.32% |
| 2022-12-31 | CN¥974.80 Million ≈ $142.64 Million |
+13.57% |
| 2021-12-31 | CN¥858.32 Million ≈ $125.60 Million |
+5.10% |
| 2020-12-31 | CN¥816.70 Million ≈ $119.51 Million |
+135.92% |
| 2019-12-31 | CN¥346.18 Million ≈ $50.66 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Aladdin Biochemical Technology Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 164.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥326.86 Million | 33.72% |
| Other Components | CN¥642.45 Million | 66.28% |
| Total Equity | CN¥969.31 Million | 100.00% |
Shanghai Aladdin Biochemical Technology Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shanghai Aladdin Biochemical Technology Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Judo Capital Holdings Ltd
AU:JDO
|
$1.18 Billion |
|
Canfor Corporation
TO:CFP
|
$1.18 Billion |
|
WHA Premium Growth Freehold And Leasehold Real Estate Investment Trust
BK:WHART
|
$1.18 Billion |
|
Iradimed Co
NASDAQ:IRMD
|
$1.18 Billion |
|
Motic Xiamen Electric Group Co Ltd
SHE:300341
|
$1.18 Billion |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
|
$1.18 Billion |
|
CHINA RISUN GROUP HD-10
F:45Y
|
$1.18 Billion |
|
Beijing Zhidemai Technology
SHE:300785
|
$1.18 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Aladdin Biochemical Technology Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,066,069,574 to 969,309,195, a change of -96,760,378 (-9.1%).
- Net income of 102,059,894 contributed positively to equity growth.
- Dividend payments of 70,457,257 reduced retained earnings.
- Other factors decreased equity by 128,363,016.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥102.06 Million | +10.53% |
| Dividends Paid | CN¥70.46 Million | -7.27% |
| Other Changes | CN¥-128.36 Million | -13.24% |
| Total Change | CN¥- | -9.08% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Aladdin Biochemical Technology Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.63x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 6.81x to 7.63x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥3.27 | CN¥22.24 | x |
| 2020-12-31 | CN¥2.95 | CN¥22.24 | x |
| 2021-12-31 | CN¥2.58 | CN¥22.24 | x |
| 2022-12-31 | CN¥2.93 | CN¥22.24 | x |
| 2023-12-31 | CN¥3.11 | CN¥22.24 | x |
| 2024-12-31 | CN¥3.84 | CN¥22.24 | x |
| 2025-12-31 | CN¥2.91 | CN¥22.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Aladdin Biochemical Technology Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.53%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.67%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 2.74x
- Recent ROE (10.53%) is below the historical average (10.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 18.40% | 30.39% | 0.54x | 1.13x | CN¥29.07 Million |
| 2020 | 9.11% | 31.78% | 0.27x | 1.06x | CN¥-7.24 Million |
| 2021 | 10.41% | 31.06% | 0.31x | 1.09x | CN¥3.53 Million |
| 2022 | 9.52% | 24.54% | 0.26x | 1.52x | CN¥-4.71 Million |
| 2023 | 8.28% | 21.30% | 0.27x | 1.45x | CN¥-17.81 Million |
| 2024 | 9.26% | 18.51% | 0.30x | 1.67x | CN¥-7.85 Million |
| 2025 | 10.53% | 14.67% | 0.26x | 2.74x | CN¥5.13 Million |
Industry Comparison
This section compares Shanghai Aladdin Biochemical Technology Co. Ltd. A's net assets metrics with peer companies in the Chemicals industry.
Industry Context
- Industry: Chemicals
- Average net assets among peers: $4,238,970,200
- Average return on equity (ROE) among peers: 9.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Aladdin Biochemical Technology Co. Ltd. A (688179) | CN¥1.19 Billion | 18.40% | 1.19x | $1.18 Billion |
| North Huajin Chemical Industries Co Ltd (000059) | $14.98 Billion | 0.47% | 1.13x | $940.88 Million |
| Sichuan Chemical Co Ltd (000155) | $505.75 Million | 22.40% | 1.18x | $3.48 Billion |
| Jiangsu Wujiang China Eastern Silk Market Co Ltd (000301) | $2.69 Billion | 5.91% | 0.33x | $11.21 Billion |
| Zangge Holding Co Ltd (000408) | $6.53 Billion | 18.58% | 0.19x | $17.56 Billion |
| Sichuan Jinlu Group Co Ltd (000510) | $754.79 Million | 9.90% | 0.56x | $2.10 Billion |
| Jilin Gpro Titanium Industry Co Ltd (000545) | $2.05 Billion | 4.97% | 0.52x | $348.02 Million |
| Aoyuan Beauty Valley Technology Co Ltd (000615) | $674.19 Million | 1.08% | 0.85x | $891.94 Million |
| Ningxia Younglight Chemicals Co Ltd (000635) | $2.90 Billion | 3.79% | 0.15x | $376.61 Million |
| Maoming Petro-Chemical Shihua Co Ltd (000637) | $771.01 Million | 16.41% | 0.10x | $286.04 Million |
| Inner Mongolia Yuan Xing Energy Co Ltd (000683) | $10.53 Billion | 6.76% | 1.09x | $3.42 Billion |
About Shanghai Aladdin Biochemical Technology Co. Ltd. A
Shanghai Aladdin Biochemical Technology Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of scientific research reagents in China and internationally. It offers chemistry and biochemicals reagents, including blocks, ligands, catalysts, chemical synthesis, laboratory chemicals, chemical biology, analytical standards, CVD and ALD precursors, and s… Read more